Navigation Links
PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
Date:4/23/2013

SOUTH PLAINFIELD, N.J., April 23, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the appointment of Mark A. Rothera as Chief Commercial Officer, reporting to Stuart W. Peltz , Ph.D., CEO of PTC Therapeutics. Mr. Rothera will be responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug ataluren.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

"It is an exciting opportunity to join PTC," stated Mr. Rothera. "Ataluren is in late-stage clinical development for patients with nonsense mutation Duchenne muscular dystrophy and cystic fibrosis. Both indications have no treatment options targeting the underlying cause of the disorder. I look forward to applying my experience in rare diseases to build a commercial function at PTC dedicated to serving patients around the world."

A veteran of the orphan drug arena, Mr. Rothera has spent 15 of his 23 years in the biopharmaceutical industry bringing new therapies to patients with rare diseases. Mr. Rothera served previously as Global President of Aegerion Pharmaceuticals Inc. where he was responsible for global commercial operations, manufacturing, and supply chain. Previously Mr. Rothera was Vice President and General Manager for the commercial operations of Shire Human Genetic Therapies in Europe, the Middle East & Africa, where he was instrumental in leading growth through geographic expansion and the successful launches of three new therapies for rare diseases across 40 countries. Prior to Shire, Mr. Rothera held global strategic and operational marketing and sales roles with the French and UK operations of Glaxo Wellcome. Mr. Rothera's previous roles included Marketing Director, Europe at Amylin Pharmaceuticals, Commercial Director, Europe at PathoGenesis and Vice President Marketing & General Manager of the United Kingdom and Ireland at Chiron. Mr. Rothera received an MA in Natural Science from Cambridge University and an MBA from INSEAD.

"We are delighted to welcome Mark as a member of our senior management team," stated Stuart W. Peltz , Ph.D., CEO of PTC Therapeutics. "Mark's extensive experience in successfully launching several global orphan products makes him ideally suited to lead our anticipated commercial efforts. His track record as a champion for transformative therapies is only matched by his continued desire to impact the lives of those affected by rare and life-threatening disorders."


About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
2. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
3. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
4. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
5. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
6. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
7. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
8. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
9. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
10. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
11. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are ... that the global medical cannabis market will reach a value of USD ... major market for the new growing industry. By the end of 2016, ... and sell medical cannabis. More conservative states like Arkansas ...
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The Radiology Business Management Association (RBMA) ... annual awards, now in their 12th year, are among the most prestigious in radiology ... 2016, the awards were retooled to recognize achievements in both large budget (over $5,000) ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... found at 9618 Huebner Road. The clinic is the group’s 7th location in San ... Dr. Ali Higgins, PT, will provide care from the clinic, which opened March 22, ...
(Date:3/24/2017)... ... 24, 2017 , ... Mlynarek Insurance Agencies, a Detroit area ... owners across eastern Michigan, is connecting with the Oxford/Orion FISH Food Pantry for ... The Oxford/Orion FISH Food Pantry works to ensure homeless, hungry, and underprivileged families ...
(Date:3/24/2017)... ... March 24, 2017 , ... In ... innovative EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 ... – with nearly 2,000 consumers (and counting) already backing the campaign. , ...
(Date:3/24/2017)... ... 2017 , ... Northridge dentists, Dr. Michel Elyson ... apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has long ... is increasingly being treated at dental offices with newly developed procedures and appliances. ...
Breaking Medicine News(10 mins):